PETAL Consortium study on T-cell and NK-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study, run by Massachusetts General Hospital, is collecting information from people around the world who have certain types of T-cell or NK-cell lymphoma. It aims to learn more about these cancers and how they are managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a mature T-cell or NK-cell lymphoma (a type of blood cancer).
- Your lymphoma can be untreated, or it may have come back after treatment (relapsed) or not responded to treatment (refractory).
- You cannot have certain other types of T-cell lymphoma, such as T-cell large granular lymphocytic leukemia, mycosis fungoides, Sézary syndrome, or primary cutaneous CD30+ disorders.
- You must be an adult able to give your own consent, and not pregnant or a prisoner.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
This trial is testing a new lab test to see how accurately it can detect T-cell lymphoma in stored tissue samples. It looks for specific genetic changes in the T-cells to help confirm or rule out the disease.
This study follows people with peripheral T-cell lymphoma (PTCL) to learn how different genetic subtypes of the disease affect their outlook and treatment response. Researchers will collect medical information, genetic test results, and long-term follow-up data.
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
Hear when a new T-Cell and NK-Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.